$CMPX
Compass Therapeutics, Inc.

2021 Q3 Form 10-Q Financial Statement

#000095017021001486 Filed on August 16, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.700M $2.166M $2.085M
YoY Change -48.97% 3.88% -36.43%
% of Gross Profit
Research & Development $3.154M $2.905M $2.985M
YoY Change -14.06% -2.68% -44.61%
% of Gross Profit
Depreciation & Amortization $100.0K $100.0K $400.0K
YoY Change -75.0% -75.0% -20.0%
% of Gross Profit
Operating Expenses $5.854M $55.69M $5.070M
YoY Change -34.67% 998.4% -41.54%
Operating Profit -$5.854M -$55.69M -$5.070M
YoY Change -34.67% 998.4% -41.54%
Interest Expense $78.00K $111.0K $242.0K
YoY Change -63.21% -54.13% -22.93%
% of Operating Profit
Other Income/Expense, Net -$121.0K -$102.0K -$471.0K
YoY Change -35.98% -78.34% 328.18%
Pretax Income -$5.975M -$55.79M -$5.541M
YoY Change -34.7% 906.88% -36.91%
Income Tax $0.00 $13.00K $16.00K
% Of Pretax Income
Net Earnings -$5.975M -$55.80M -$5.557M
YoY Change -34.7% 904.21% -36.92%
Net Earnings / Revenue
Basic Earnings Per Share -$0.10 -$1.07
Diluted Earnings Per Share -$96.85K -$1.075M -$106.6K
COMMON SHARES
Basic Shares Outstanding 61.69M 51.91M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.51M $31.21M $65.37M
YoY Change -54.05% -52.26%
Cash & Equivalents $25.50M $31.20M $65.37M
Short-Term Investments
Other Short-Term Assets $3.063M $3.326M $1.917M
YoY Change 32.37% 73.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $28.57M $34.53M $67.29M
YoY Change -50.59% -48.68%
LONG-TERM ASSETS
Property, Plant & Equipment $1.435M $1.178M $2.829M
YoY Change -40.65% -58.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $320.0K $320.0K $69.00K
YoY Change -27.27% 363.77%
Total Long-Term Assets $6.327M $6.338M $3.161M
YoY Change 121.38% 100.51%
TOTAL ASSETS
Total Short-Term Assets $28.57M $34.53M $67.29M
Total Long-Term Assets $6.327M $6.338M $3.161M
Total Assets $34.90M $40.87M $70.45M
YoY Change -42.5% -41.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $868.0K $559.0K $1.581M
YoY Change 1.64% -64.64%
Accrued Expenses $1.998M $1.174M $2.574M
YoY Change 47.13% -54.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.744M $5.611M $7.454M
YoY Change -49.82% -24.72%
Total Short-Term Liabilities $7.683M $8.393M $11.61M
YoY Change -20.57% -27.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $5.590M
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $3.328M $3.604M
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $5.590M
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.683M $8.393M $11.61M
Total Long-Term Liabilities $0.00 $0.00 $5.590M
Total Liabilities $11.01M $12.00M $17.20M
YoY Change -17.85% -30.25%
SHAREHOLDERS EQUITY
Retained Earnings -$220.6M -$214.6M -$133.9M
YoY Change 60.33%
Common Stock $244.5M $243.5M $187.1M
YoY Change 30.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $23.89M $28.88M $53.25M
YoY Change
Total Liabilities & Shareholders Equity $34.90M $40.87M $70.45M
YoY Change -42.5% -41.98%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$5.975M -$55.80M -$5.557M
YoY Change -34.7% 904.21% -36.92%
Depreciation, Depletion And Amortization $100.0K $100.0K $400.0K
YoY Change -75.0% -75.0% -20.0%
Cash From Operating Activities -$3.457M -$5.939M -$13.06M
YoY Change -51.78% -54.53% -32.85%
INVESTING ACTIVITIES
Capital Expenditures -$367.0K -$614.0K -$16.00K
YoY Change 5142.86% 3737.5% -106.4%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $55.00K
YoY Change -100.0%
Cash From Investing Activities -$367.0K -$614.0K $39.00K
YoY Change 5142.86% -1674.36% -115.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.875M -1.875M 53.09M
YoY Change -29.96% -103.53%
NET CHANGE
Cash From Operating Activities -3.457M -5.939M -13.06M
Cash From Investing Activities -367.0K -614.0K 39.00K
Cash From Financing Activities -1.875M -1.875M 53.09M
Net Change In Cash -5.699M -8.428M 40.07M
YoY Change -42.16% -121.03% -303.39%
FREE CASH FLOW
Cash From Operating Activities -$3.457M -$5.939M -$13.06M
Capital Expenditures -$367.0K -$614.0K -$16.00K
Free Cash Flow -$3.090M -$5.325M -$13.05M
YoY Change -56.86% -59.18% -33.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001738021
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
982000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
34534000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
50202000
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1867000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3604000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q2 us-gaap Liabilities
Liabilities
11997000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1178000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1126000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
dei Entity File Number
EntityFileNumber
001-39696
dei Entity Registrant Name
EntityRegistrantName
COMPASS THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-4876496
dei Entity Address Address Line1
EntityAddressAddressLine1
80 Guest St.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 601
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02135
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
500-8099
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
CMPX
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61694565
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31208000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47076000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3326000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3126000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
210000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
263000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4630000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000
CY2021Q2 us-gaap Assets
Assets
40872000
CY2020Q4 us-gaap Assets
Assets
51911000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
559000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1061000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1174000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1571000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1049000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
5611000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7467000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8393000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10099000
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Liabilities
Liabilities
11966000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62323000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52117000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61666000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51221000
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
243503000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
191348000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-214634000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-151408000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
28875000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
39945000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40872000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51911000
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2905000
CY2020Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2985000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7609000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6556000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2166000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2085000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4798000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4345000
CY2021Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
50618000
CY2020Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
50618000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
55689000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
5070000
us-gaap Operating Expenses
OperatingExpenses
63025000
us-gaap Operating Expenses
OperatingExpenses
10901000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-55689000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5070000
us-gaap Operating Income Loss
OperatingIncomeLoss
-63025000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10901000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-102000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-471000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-185000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1026000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-55791000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5541000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63210000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11927000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-55804000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-5557000
us-gaap Net Income Loss
NetIncomeLoss
-63223000
us-gaap Net Income Loss
NetIncomeLoss
-11959000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-124758000
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
129870000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6902000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
53581000
CY2020Q2 cmpx Payment To Non Participating Members Upon Consummation Of Merger
PaymentToNonParticipatingMembersUponConsummationOfMerger
-69000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.07
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.23
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.16
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51913000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13603000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51582000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10335000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
39945000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
948000
CY2021Q1 cmpx Net Loss
NetLoss
7422000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
33471000
CY2021Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
50300000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
908000
CY2021Q2 cmpx Net Loss
NetLoss
-55804000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
28875000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-118603000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
247000
CY2020Q1 cmpx Net Loss
NetLoss
6402000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
183000
CY2020Q2 cmpx Net Loss
NetLoss
5557000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
53250000
us-gaap Profit Loss
ProfitLoss
-63223000
us-gaap Profit Loss
ProfitLoss
-11959000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
304000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
44000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-8000
cmpx Non Cash Interest Expense
NonCashInterestExpense
22000
cmpx Non Cash Interest Expense
NonCashInterestExpense
50000
us-gaap Share Based Compensation
ShareBasedCompensation
1856000
us-gaap Share Based Compensation
ShareBasedCompensation
430000
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
50618000
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
0
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-556000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
518000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
200000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-32000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-502000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
952000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-398000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1998000
cmpx Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-495000
cmpx Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-1050000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11544000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13061000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
424000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16000
cmpx Payments For Asset Acquisition Costs
PaymentsForAssetAcquisitionCosts
318000
cmpx Payments For Asset Acquisition Costs
PaymentsForAssetAcquisitionCosts
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
115000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
55000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-627000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
39000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60482000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5517000
us-gaap Repayments Of Debt
RepaymentsOfDebt
3750000
us-gaap Repayments Of Debt
RepaymentsOfDebt
1875000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3750000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53090000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15921000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
40068000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47339000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25566000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31418000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65634000
us-gaap Interest Paid Net
InterestPaidNet
226000
us-gaap Interest Paid Net
InterestPaidNet
486000
cmpx Noncash Or Part Noncash Acquisition Of Equipment Included In Accrued Expenses
NoncashOrPartNoncashAcquisitionOfEquipmentIncludedInAccruedExpenses
0
cmpx Noncash Or Part Noncash Acquisition Of Equipment Included In Accrued Expenses
NoncashOrPartNoncashAcquisitionOfEquipmentIncludedInAccruedExpenses
0
cmpx Noncash Or Part Noncash Deferred Offering Costs Included In Accrued Expenses
NoncashOrPartNoncashDeferredOfferingCostsIncludedInAccruedExpenses
0
cmpx Noncash Or Part Noncash Deferred Offering Costs Included In Accrued Expenses
NoncashOrPartNoncashDeferredOfferingCostsIncludedInAccruedExpenses
-1384000
cmpx Non Cash Or Part Non Cash Payment To Non Participating Investors Within Accrued Expenses
NonCashOrPartNonCashPaymentToNonParticipatingInvestorsWithinAccruedExpenses
0
cmpx Non Cash Or Part Non Cash Payment To Non Participating Investors Within Accrued Expenses
NonCashOrPartNonCashPaymentToNonParticipatingInvestorsWithinAccruedExpenses
-69000
cmpx Noncash Or Part Noncash Right Of Use Asset Acquired Through Operating Leases
NoncashOrPartNoncashRightOfUseAssetAcquiredThroughOperatingLeases
5148000
cmpx Noncash Or Part Noncash Right Of Use Asset Acquired Through Operating Leases
NoncashOrPartNoncashRightOfUseAssetAcquiredThroughOperatingLeases
0
cmpx Noncash Or Part Noncash Acquisition Of Business
NoncashOrPartNoncashAcquisitionOfBusiness
50300000
cmpx Noncash Or Part Noncash Acquisition Of Business
NoncashOrPartNoncashAcquisitionOfBusiness
0
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-03-20
us-gaap Proceeds From Sale Of Available For Sale Securities Equity
ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
132000000.0
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
15000000.0
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31200000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5975000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7061000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4797000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5935000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1178000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1126000
CY2021Q2 us-gaap Depreciation
Depreciation
100000
CY2020Q2 us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
900000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1571000
CY2021Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
572000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
976000
CY2021Q2 cmpx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
356000
CY2020Q4 cmpx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
212000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
0
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
326000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
246000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
57000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1174000
CY2021Q2 cmpx Long Term Debt Before Unamortized Discount Current
LongTermDebtBeforeUnamortizedDiscountCurrent
5625000
CY2020Q4 cmpx Long Term Debt Before Unamortized Discount Current
LongTermDebtBeforeUnamortizedDiscountCurrent
7500000
CY2021Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
14000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
33000
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
5611000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7467000
CY2021Q2 cmpx Long Term Debt Before Unamortized Discount Noncurrent
LongTermDebtBeforeUnamortizedDiscountNoncurrent
0
CY2020Q4 cmpx Long Term Debt Before Unamortized Discount Noncurrent
LongTermDebtBeforeUnamortizedDiscountNoncurrent
1875000
CY2021Q2 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
0
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
8000
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1867000
cmpx Number Of Operating Lease
NumberOfOperatingLease
1
CY2021Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y5M
CY2021Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0625
CY2021Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y11M
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
749000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1315000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1348000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1382000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
426000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5220000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
567000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4653000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1049000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3604000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1856000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
430000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.95
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
7000
us-gaap Investment Income Interest
InvestmentIncomeInterest
24000
us-gaap Investment Income Interest
InvestmentIncomeInterest
48000
CY2021Q2 us-gaap Interest Expense
InterestExpense
111000
CY2020Q2 us-gaap Interest Expense
InterestExpense
242000
us-gaap Interest Expense
InterestExpense
253000
us-gaap Interest Expense
InterestExpense
518000
CY2020Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-236000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-556000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
44000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-102000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-471000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-185000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1026000

Files In Submission

Name View Source Status
0000950170-21-001486-index-headers.html Edgar Link pending
0000950170-21-001486-index.html Edgar Link pending
0000950170-21-001486.txt Edgar Link pending
0000950170-21-001486-xbrl.zip Edgar Link pending
cmpx-20210630.htm Edgar Link pending
cmpx-20210630.xsd Edgar Link pending
cmpx-20210630ex10_1.htm Edgar Link pending
cmpx-20210630ex31_1.htm Edgar Link pending
cmpx-20210630ex31_2.htm Edgar Link pending
cmpx-20210630ex32_1.htm Edgar Link pending
cmpx-20210630ex32_2.htm Edgar Link pending
cmpx-20210630_cal.xml Edgar Link unprocessable
cmpx-20210630_def.xml Edgar Link unprocessable
cmpx-20210630_htm.xml Edgar Link completed
cmpx-20210630_lab.xml Edgar Link unprocessable
cmpx-20210630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending